There’s all sorts of products out there. Who knows, ‘Reuma King’ or ‘Contra Reumas’ might do something, but that’s probably all the fraudulent hidden dexamethasone inside… Beware+++ #ACR25 FDA Update @RheumNow https://t.co/rco4wTXBjO

• https://x.com/drdavidliew/status/1983245491451376077/photo/1

US Electronic Health Record cohort 2000+pts Incidence Heart Failure over 10 yrs 6.8% HF asso w/ Older Male Lower eGFR Hypertensive medication Diabetes TTMTS MTX, TNFi Higher CRP Probably surrogates for High Disease Activity... How do we detect it? Maybe not by using the https://t.co/s9SjEyk3WF

• https://x.com/AurelieRheumo/status/1983242428447424710/photo/1
• https://x.com/AurelieRheumo/status/1983242428447424710/photo/1

@RheumNow Obinutuzumab for lupus nephritis was a very recent FDA addition two weeks ago, and we’ll play catch-up with the hematologists to get familiar with it, including its safety profile #ACR25 FDA Update @RheumNow https://t.co/h6bf4roGzB

• https://x.com/drdavidliew/status/1983238079105409478/photo/1
• https://x.com/drdavidliew/status/1983238079105409478/photo/1
• https://x.com/drdavidliew/status/1983238079105409478/photo/1

Cooper et al. FAERS based analysis of adverse events with avacopan.3658 patients on avacopan, 30 million overall. DILI seems to be the big concern, with Reporting Odds Ratio of >17. @RheumNow #ACR25 Abstr#2519 https://t.co/1LoDvRHkqa

• https://x.com/RichardPAConway/status/1983234558985417164/photo/1

#ACR25 Abstr#LB14 Deep blood & tissue depletion are not just confined to CAR-T. Exploratory analysis of REGENCY showed Obinutuzumab induced near-complete depletion & significantly reduced plasma in kidney tissue vs PBO @RheumNow https://t.co/r1danWBM7D

• https://x.com/Yuz6Yusof/status/1983232738934030504/photo/1

After melanoma, should RA patients stop DMARDs? These VA data (n=644) showed no mortality signal, and trending to survival benefit with b/tsDMARDs Provisos over methotrexate, invasive disease etc, but don’t hold off treating the RA because of melanoma #ACR25 ABST2237 @RheumNow https://t.co/l9n1V6YVln

• https://x.com/drdavidliew/status/1983229116469162290/photo/1

#IL2 #Rx in active #SLE? Maybe 🤔 IL2 is tricky - low dose May help #SLE but too much of a good thing may have a neg impact. RCT of IL2i in #SLE gave a good dose response and improved TRegs. #ACRBest #ACR25 @RheumNow @ACRheum #LB01 https://t.co/F61qz5x5We

• https://x.com/Janetbirdope/status/1983227740267422026/photo/1
• https://x.com/Janetbirdope/status/1983227740267422026/photo/1

Adverse events from avacopan the WHO pharmacovigilence database (VigiBase) Not a lot new - infections happen, hepatic events happen but seem to be somewhat rare Pharmacovigilence is hard; most events go unreported & we often have the classic "denominator problem" (ie we saw https://t.co/28tYkXv0Lz

• https://x.com/EBRheum/status/1983225627403563379/photo/1

In the CLOSE-UP study of UPA in RA - 61% in remission with responses sustained to 24 mo - Benefit consistent irrespective of prior DMARD use - No new safety signals @RheumNow #ACR25 Abstract#2281

#ACR25 Abstr#LB10 Promising 4-Year data of Deucravacitinib in blinded phase 2 RCT +LTE study showed efficacy inc. LLDAS and CLASI-50 response were maintained/improved over time in #SLE No concerning safety signal. Looking forward to Phase 3 results next year @RheumNow https://t.co/fZv82zJ6Q4

• https://x.com/Yuz6Yusof/status/1983220916264771657/photo/1

Serrano-Combarro et al. Abatacept in RA-ILD. 343 patients. Progressive ILD in 23%. Similar to the numbers progressing on baricitinib by same group. Previous MTX treatment appears to REDUCE risk (OR 0.45). Disease activity increases risk (OR 1.29). @RheumNow #ACR25 Abstr#2265 https://t.co/0tl0kGgm5p

• https://x.com/RichardPAConway/status/1983218705136800239/photo/1

#ACR25 How hard will you go & at what cost? A study in China using CD20/BCMA Bispecific autologous CAR-T showed profound depletion, normalisation of abs and good response in #SLE (10/11 had LN). But 2 had G3 infections & cytopenia. Presenters said some had IVIG @RheumNow #ACRBest https://t.co/TF0wpib5rr

• https://x.com/Yuz6Yusof/status/1983218032924119234/photo/1
• https://x.com/Yuz6Yusof/status/1983218032924119234/photo/1

Starting biologic early could save more than joints. In 329 RA pts, first-line anti-TNF reduced testing and hospitalization costs vs csDMARDs across Europe. Earlier targeted therapy pay off in outcomes and economics. @RheumNow #ACR25 Abstract#2271 https://t.co/zZ32CpT36d

• https://x.com/JihaRheum/status/1983217698508013990/photo/1

#1747 Serious infections ~2× more common in RA-LD, esp RA-ILD. Pulmonary, bacterial, viral & fungal infections all increased, underscoring need for tailored prevention and vaccination. @RheumNow #ACR25 https://t.co/soyzqLk7Vj

• https://x.com/DrMiniDey/status/1983215181129031750/photo/1

#1746 In large US RA cohort, elevated GDF-15 & pentraxin-3 levels linked to prevalent RA-ILD; high GDF-15 predicted future ILD risk. Other fibrosis-related mediators from IPF or heart failure were not associated, suggesting RA-ILD has distinct pathogenic pathways @RheumNow #ACR25